Clinical Trials Logo

Clinical Trial Summary

This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy.


Clinical Trial Description

In this study, participants' data will be extracted from their medical records or collected based on clinical and laboratory assessments during routine visits, per the site's standard of care. Blood samples collected from the participants during routine visits will also be used for analysis. The study will be conducted in two parts: Cross-Sectional part during which a single measurement of NfL levels will be performed using blood samples collected from asymptomatic carriers, and symptomatic hATTR amyloidosis patients; Longitudinal part during which measurements of NfL levels will be performed over time using blood samples (already collected from the participants during routine visits) from asymptomatic carriers and patients with symptomatic hATTR amyloidosis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06360289
Study type Observational
Source Alnylam Pharmaceuticals
Contact Alnylam Clinical Trial Information Line
Phone 1-877-ALNYLAM
Email clinicaltrials@alnylam.com
Status Recruiting
Phase
Start date April 25, 2024
Completion date April 2027